炎症反应在糖尿病性黄斑水肿中的作用研究进展

黄圣嫒, 马高恩

【作者机构】 海南医科大学第一附属医院眼科
【分 类 号】 R587.2
【基    金】 国家外国专家项目(G2022026027L) 河南省医学科技攻关计划省部共建项目(SBGJ202102190)。
全文 参考文献 出版信息
炎症反应在糖尿病性黄斑水肿中的作用研究进展

炎症反应在糖尿病性黄斑水肿中的作用研究进展

黄圣嫒 马高恩

海南医科大学第一附属医院眼科,海南海口 570100

[摘要] 糖尿病性黄斑水肿(DME)是糖尿病视网膜病变视力损伤的主要原因之一,可发生在糖尿病视网膜病变中的任一阶段。既往研究多强调血管内皮生长因子介导的血-视网膜屏障破坏,部分患者对抗血管内皮生长因子的治疗反应欠佳,因此深入探索其他分子病理网络仍是该领域重点。近年来,“炎症-血管”双驱动新模式可促进DME的研究进展。本文分析小胶质细胞、米勒细胞等关键细胞的活化过程,并探讨NF-κB、JAK/STAT、NLRP3炎症小体等重要信号通路的相互影响,进一步讨论炎症视角下的诊疗新策略,包括新型生物标志物的发掘、靶向炎症药物的临床转化,以及基于炎症分型的个体化治疗理念,以展望DME炎症研究的未来方向,为该病基础研究与临床实践提供新思路。

[关键词] 糖尿病性黄斑水肿;炎症反应;血-视网膜屏障;细胞因子;个体化治疗

糖尿病视网膜病变是糖尿病最常见的微血管并发症之一,糖尿病性黄斑水肿(diabetic macular edema,DME)是其导致视力下降和视功能受损的关键类型[1-2]。全球约超过1/3糖尿病患者罹患糖尿病视网膜病变,约10%可进展为DME[3]。DME的核心病理机制为血-视网膜屏障的完整性受损,进而导致血管渗漏及视网膜水肿的发生[4-5]。目前,抗血管内皮生长因子(vascular endothelial growth factor,VEGF)药物如雷珠单抗和康柏西普等已成为全球公认的一线治疗方案,仍有30%~40%的患者反应欠佳,且反复眼内注射不仅带来眼内炎、视网膜脱离等风险,还加重患者的经济负担,因此探寻新的治疗靶点至关重要[6-9]。

近年来,“炎症学说”在DME发病机制中的地位日益凸显。研究显示,DME本质上属于慢性低度炎症性疾病[10]。在高糖、氧化应激及晚期糖基化终末产物积累等多种因素协同作用下,固有免疫机制与适应性免疫反应被激活,大量炎症因子释放,破坏血-视网膜屏障并上调VEGF表达,形成恶性循环[11]。因此探讨DME中的炎症机制,研发针对炎症靶点的新型诊疗策略,已成为当前研究的热点与突破口。本文系统论述炎症反应在DME进展中的分子机制、关键生物标志物及相关抗炎治疗策略,探讨靶向炎症通路联合抗VEGF治疗的潜力,以期为DME精准诊疗提供理论依据。

1 DME中炎症反应的核心细胞与分子机制

1.1 关键炎症细胞的激活与作用

视网膜免疫防御体系中,固有免疫细胞扮演炎症反应“哨兵”角色。作为主要常驻免疫细胞,小胶质细胞在生理下呈静息“监视”态,维持视网膜微环境稳态。DME的高糖、缺氧等信号可打破稳态促使其快速激活,迁移至病变区域释放细胞毒性物质损伤神经元和血管内皮细胞,进一步加剧炎症[12-13]。单细胞RNA测序研究显示,DME中小胶质细胞并非简单的M1型(促炎)/M2型(抗炎)二元极化,而是呈现高度异质性,不同亚群分别表达不同的促炎因子、趋化因子和补体成分,共同构成视网膜内炎症微环境[14]。米勒细胞作为贯穿视网膜全层的主要胶质细胞,对维持视网膜结构完整与内环境稳态具有重要的作用。在DME中其发生反应性胶质增生,胶质纤维酸性蛋白表达上调,并成为视网膜内VEGF及白细胞介素-6、白细胞介素-8、单核细胞趋化蛋白-1等炎症介质的重要来源[15]。此外,米勒细胞通过调节水通道蛋白4和钾离子通道4.1直接参与并调控视网膜水液代谢及钾离子稳态。炎症状态下两者的表达和定位异常,导致细胞内液体积聚,是形成黄斑囊样水肿的直接原因之一[16-17]。

视网膜色素上皮细胞是构成外层血-视网膜屏障的重要部分。高糖状态可诱导视网膜色素上皮细胞发生上皮-间质转化,使其丧失紧密连接并分泌多种基质金属蛋白酶和炎症因子,减弱原有外屏障功能,放大炎症反应加剧黄斑水肿。除局部固有细胞外,循环炎症细胞也参与DME进展。研究显示,外周血中性粒细胞与淋巴细胞比值、单核细胞与淋巴细胞比值升高,可作为评估DME的炎症负荷程度及预后潜在生物标志物[18]。在持续高糖环境刺激下,视网膜血管内皮细胞表面黏附分子表达上调,促进中性粒细胞、单核细胞等炎症细胞滚动、黏附、迁移与浸润,释放蛋白酶和活性氧,攻击紧密连接和基底膜,破坏血-视网膜屏障[19-20]。研究显示,DME患者体内中性粒细胞胞外诱捕网既作为物理支架加剧局部炎症反应,又能激活凝血系统,促进微血栓形成,加剧血管渗漏和黄斑水肿进展[21]。

1.2 关键炎症信号通路的交叉对话

上述细胞活化依赖于复杂信号通路网络,其中几条核心通路在DME炎症中起“枢纽”作用。

高糖、晚期糖基化终末产物、氧化应激,以及肿瘤坏死因子-α、白细胞介素-1β等上游刺激均可激活IκB激酶复合物,促进核因子κB(nuclear factor κB,NF-κB)p65/p50入核并启动下游肿瘤坏死因子-α、白细胞介素-1β、白细胞介素-6、环氧合酶-2、诱生型一氧化氮合酶、细胞间黏附分子-1及血管细胞黏附分子-1等大量炎症相关基因的转录,形成正反馈循环[22-23]。因此,靶向抑制NF-κB信号通路有望从源头阻断炎症介质的级联放大,为糖皮质激素等广谱抗炎药物的作用机制提供重要的分子靶点解释。

核苷酸结合结构域富含亮氨酸重复序列和含热蛋白结构域受体3(nucleotide-binding domain leucinerich repeat and pyrin domain-containing receptor 3,NLRP3)炎症小体是介导代谢应激向炎症转化的核心。在DME中,高糖、线粒体功能障碍产生的活性氧及晶体渗透压改变,均可作为“第二信号”激活NLRP3炎症小体,诱导胱天蛋白酶-1前体的活化,将无活性的白细胞介素-1β与白细胞介素-18前体切割加工,使其转变为成熟的促炎性细胞因子,并最终分泌至细胞外[24-27]。白细胞介素-1β能进一步放大NF-κB信号,招募更多炎症细胞,是DME炎症放大环的核心环节[28]。开发针对NLRP3炎症小体及其下游核心细胞因子如白细胞介素-1β的特异性抑制剂,是打破难治性DME炎症恶性循环的关键干预手段。

JAK/STAT信号通路是近年来DME的前沿探索方向。白细胞介素-6家族等多种细胞因子,通过与相应受体结合,激活JAK,磷酸化STAT(主要为STAT3)形成二聚体结构,转位入核,调控靶基因转录活性。JAK/STAT信号通路激活既直接促进炎症因子产生,又上调VEGF表达,将炎症与血管渗漏紧密联系,同时为JAK抑制剂应用于DME治疗提供理论基础、实现“抗炎+抗血管”双重抑制提供坚实的理论基础[29-30]。

1.3 炎症与血管渗漏的恶性循环

炎症和血管异常在DME中并非相互独立。肿瘤坏死因子-α孙昊白细胞介素-1β等炎症因子可诱导密封蛋白-5、闭合蛋白和紧密连接蛋白-1发生磷酸化、内化和降解,最终导致血-视网膜屏障完整性破坏[31]。同时,炎症通路的激活又上调VEGF的表达,间接加剧血管渗漏,外渗血浆成分(如纤维蛋白原、凝血酶、补体蛋白)进一步激活小胶质细胞和米勒细胞,招募更多炎症细胞进入病灶,加剧炎症反应,最终构成DME慢性进展的恶性循环。这一机制可解释部分患者单纯抗VEGF治疗反应有限的原因。

2 炎症机制指导下的DME诊疗新策略

2.1 炎症活动的评估与分型

尽管DME的核心分子机制已较明确,但其表现、病程演变及治疗反应仍存在显著异质性,因此精准评估验证活性并进行分型很关键。相较于单纯依据解剖形态的传统分型方式,基于发病机制的分类方法能更为精准地预测不同治疗手段所产生的反应,有助于临床医师“量体裁衣”,避免无效或低效的治疗。目前广泛接受表型如下:①血管主导型。临床为黄斑区囊样改变、硬性渗出环,光学相干断层扫描血管成像显示广泛毛细血管缺失,此类患者通常对抗VEGF反应良好。②炎症主导型。临床为弥漫性视网膜增厚,光学相干断层成像可见大量视网膜内层强反射灶,房水检测显示白细胞介素-6等炎症因子水平升高。此类患者可能需要早期联合或首选抗炎治疗如激素或新型抗炎药。③混合型。兼具血管和炎症的特征,治疗上可能需要抗VEGF与抗炎药物的联合或序贯治疗。

2.2 指导分型的生物标志物

为了准确区分上述不同表型,寻找能客观反映眼内微环境的生物标志物成为连接“机制认知”与“精准分型”的工具。常见的游离脂肪酸与光学相干断层成像传统检查方法,主要反映血管渗漏和视网膜结构形态变化,仅能间接评估炎症活动性,而新型生物标志物为精准分型提供清晰的逻辑链条。①眼内液分子标志物:通过对房水或玻璃体液样本分析,能同时定量检测房水中数十种细胞因子和趋化因子的表达水平,可直接反映眼内微环境的真实状态。研究显示,DME患者房水样本中的白细胞介素-6、白细胞介素-8、IP-10及单核细胞趋化蛋白-1等炎症因子水平不仅与黄斑中央视网膜厚度相关,还与患者的视力预后有关[32-33]。因此可根据房水炎症因子谱对DME进行分子分型,进而调整个体化治疗方案[34]。以白细胞介素-6水平升高为主的“炎症主导型”DME患者常对抗VEGF治疗反应不佳,而对抗炎治疗更敏感[35]。②无创影像学标志物:影像学生物标志物能以无创方式评估炎症反应。光学相干断层成像中的视网膜内层强反射灶表现为点状或团块状病灶,与视网膜神经纤维层反射率相近,组织学研究表明可能是活化的米勒细胞末端、迁移中的巨噬细胞,或含有脂质沉积的巨噬细胞[36]。其数量、分布及其动态变化与DME炎症活跃程度和治疗反应存在明显关联。此外,光学相干断层扫描血管成像技术能无创显示视网膜深层毛细血管网,量化毛细血管无灌注区面积及黄斑中心凹无血管区形态变化。这些由慢性炎症驱动的微血管损伤指标间接反映炎症严重程度[37]。

2.3 靶向炎症的治疗药物进展

基于对炎症通路的认识,靶向炎症策略日益丰富,从广谱抗炎药到精准靶向药物,为DME患者提供更多选择。

糖皮质激素作为一类经典的广谱抗炎药物,通过抑制信号通路下调炎症因子与VEGF的表达。地塞米松、氟轻松的玻璃体内缓释植入剂能延长药效,较少注射频次,特别适用于有玻璃体黄斑牵拉、已植入人工晶状体,以及对抗VEGF治疗反应不佳的DME患者。然受限于高眼压及白内障的不良反应,通常不将其作为首选治疗方案[38]。

尽管抗VEGF药物的主要作用靶点为VEGF,但其具备一定程度的抗炎功效。临床数据显示,对DME患者施以玻璃体内阿柏西普注射,可使其房水中白细胞介素-6、细胞间黏附分子-1等一系列炎症因子的表达水平发生显著下调,提示抗VEGF治疗可能通过“一石二鸟”的方式,同时抑制血管和炎症两条通路[39]。

针对特定炎症分子的靶向药物是当前的研发前沿,旨在实现更高疗效和更少不良反应,可代表DME今后的治疗方向。①抗白细胞介素-6/白细胞介素-6受体疗法:白细胞介素-6在DME炎症网络中处于核心位置,针对该通路的药物成为理想选择。②JAK抑制剂:JAK抑制剂如芦可替尼、巴瑞替尼通过阻断JAK/STAT信号通路,理论上可同时抑制多种细胞因子如白细胞介素-6和VEGF下游信号,实现“双通路”抑制[40]。③整合素拮抗剂:抗α1β1整合素如利妥昔单抗在临床试验中显示降低视网膜厚度的潜力,为抑制炎症细胞浸润提供新思路[41]。④补体抑制剂:随着补体系统在DME中作用逐渐明确,补体抑制剂如佩格塞塔科普兰已进入DME临床研究阶段,有望从另一角度阻断炎症级联反应[42]。⑤NLRP3炎症小体抑制剂:近年来,靶向抑制NLRP3如MCC950已成为极具潜力的前沿方向。阻断NLRP3不仅能减少白细胞介素-1β和白细胞介素-18等下游促炎性细胞因子的成熟与释放,而且能从上游截断与细胞焦亡相关的级联反应。在体内实验中,玻璃体腔注射MCC950不仅显著改善高糖诱导的视网膜内皮细胞功能障碍,还能减少微血管渗漏和炎症细胞浸润,为“炎症主导型”DME提供一种具有高度特异性的全新治疗途径[43-44]。

3 小结与展望

随着对DME炎症机制认识的不断深入,DME治疗已从单纯强调VEGF驱动,逐步转向“炎症-血管”双通路整合干预。小胶质细胞和米勒细胞活化、NF-κB/NLRP3/JAK-STAT信号通路异常及炎症与血管渗漏间的正反馈是DME持续进展和治疗差异的重要基础。今后仍需借助单细胞测序、空间转录组和多模态影像等技术,进一步描绘DME炎症微环境图谱,筛选可靠的分层标志物,并通过更多前瞻性、多中心研究验证新型抗炎靶向药物的疗效与安全性。基于炎症在DME发病中的早期驱动作用,探索“治疗时机前移”策略,从源头阻断或延缓DME的发生,实现由“治已病”向“防未病”的防治结合新理念。

利益冲突声明:所有作者均声明不存在利益冲突。

[参考文献]

[1]Kha R,Kapucu Y,Indrakumar M,et al. Diabetic retinopathy further increases risk of cardiovascular disease mortality in a high-risk cohort [J]. Sci Rep,2025,15(1):4811.

[2]Figueira J,Henriques J,Carneiro Â,et al. Guidelines for the management of center-involving diabetic macular edema:treatment options and patient monitorization [J]. Clin Ophthalmol,2021,15:3221-3230.

[3]Teo Z L,Tham Y C,Yu M,et al. Global prevalence of diabetic retinopathy and projection of burden through 2045:systematic review and meta-analysis [J]. Ophthalmology,2021,128(11):1580-1591.

[4]Zhang J,Zhang J,Zhang C,et al. Diabetic macular edema:current understanding,molecular mechanisms and therapeutic implications [J]. Cells,2022,11(21):3362.

[5]Chauhan M Z,Rather P A,Samarah S M,et al. Current and novel therapeutic approaches for treatment of diabetic macular edema [J]. Cells,2022,11(12):1950.

[6]Virgili G,Curran K,Lucenteforte E,et al. Anti-vascular endothelial growth factor for diabetic macular oedema:a network meta-analysis [J]. Cochrane Database Syst Rev,2023,2023(6):Cd007419.

[7]Chen-Li G,Martinez-Archer R,Coghi A,et al. Beyond VEGF:angiopoietin-tie signaling pathway in diabetic retinopathy [J]. J Clin Med,2024,13(10):2778.

[8]Eissa M,Kalogeropoulos D,Evans W,et al. Efficacy of ozurdex implants as second-line therapy for non-responders to anti-VEGF in retinal vein occlusion-associated macular edema:a retrospective cohort study [J]. Ir J Med Sci,2025,194(2):745-750.

[9]Heinke A,Warter A,Cavichini M,et al. Combination intravitreal steroid and anti-VEGF therapy for double-monotherapy-resistant chronic diabetic macular edema [J]. Ophthalmic Surg Lasers Imaging Retina,2025,56(11):664-671.

[10]Tilg H,Zmora N,Adolph T E,et al. The intestinal microbiota fuelling metabolic inflammation [J]. Nat Rev Immunol,2020,20(1):40-54.

[11]Vujosevic S,Lupidi M,Donati S,et al. Role of inflammation in diabetic macular edema and neovascular agerelated macular degeneration [J]. Surv Ophthalmol,2024,69(6):870-881.

[12]Church K A,Rodriguez D,Vanegas D,et al. Models of microglia depletion and replenishment elicit protective effects to alleviate vascular and neuronal damage in the diabetic murine retina [J]. J Neuroinflammation,2022,19(1):300.

[13]Xie H,Zhang C,Liu D,et al. Erythropoietin protects the inner blood-retinal barrier by inhibiting microglia phagocytosis via Src/Akt/cofilin signalling in experimental diabetic retinopathy [J]. Diabetologia,2021,64(1):211-225.

[14]Hu Z,Mao X,Chen M,et al. Single-cell transcriptomics reveals novel role of microglia in fibrovascular membrane of proliferative diabetic retinopathy [J]. Diabetes,2022,71(4):762-773.

[15]Zhang Q,Qi S,You J,et al. The role of retinal glial cells and related factors in macular edema [J]. Biochem Biophys Res Commun,2024,695:149415.

[16]Chen Z,Liu B,Zhou D,et al. AQP4 regulates ferroptosis and oxidative stress of Muller cells in diabetic retinopathy by regulating TRPV4 [J]. Exp Cell Res,2024,439(1):114087.

[17]Netti V,Cocca M A,Cutrera N,et al. Osteopontin regulates AQP4 expression by TRPV4 activation in Müller cells:implications for retinal homeostasis [J]. Mol Neurobiol,2025,62(4):4769-4784.

[18]Yalinbas Yeter D,Eroglu S,Sariakcali B,et al. The usefulness of monocyte-to-high density lipoprotein and neutrophil-to-lymphocyte ratio in diabetic macular edema prediction and early anti-VEGF treatment response [J]. Ocul Immunol Inflamm,2022,30(4):901-906.

[19]Abu El-Asrar A M,Nawaz M I,Ahmad A,et al. ADAMTS13 improves endothelial function and reduces inflammation in diabetic retinopathy [J]. Cells,2025,14(2):85.

[20]Zhou J,Xie Z. Endostatin inhibits blood-retinal barrier breakdown in diabetic rats by increasing the expression of ICAM-1 and VCAM-1 and decreasing the expression of VEGF [J]. Comput Math Methods Med,2022,2022:5105866.

[21]Stepp M A,Menko A S. Immune responses to injury and their links to eye disease [J]. Transl Res,2021,236:52-71.

[22]Choi Y H. Reduction of high glucose-induced oxidative injury in human retinal pigment epithelial cells by sarsasapogenin through inhibition of ROS generation and inactivation of NF-κB/NLRP3 inflammasome pathway [J].Genes Genomics,2023,45(9):1153-1163.

[23]Li W,Liu X,Tu Y,et al. Dysfunctional Nurr1 promotes high glucose-induced Müller cell activation by upregulating the NF-κB/NLRP3 inflammasome axis [J].Neuropeptides,2020,82:102057.

[24]Raman K S,Matsubara J A. Dysregulation of the NLRP3 inflammasome in diabetic retinopathy and potential therapeutic targets [J]. Ocul Immunol Inflamm,2022,30(2):470-478.

[25]Kong H,Zhao H,Chen T,et al. Targeted P2X7/NLRP3 signaling pathway against inflammation,apoptosis,and pyroptosis of retinal endothelial cells in diabetic retinopathy [J]. Cell Death Dis,2022,13(4):336.

[26]Kuo C Y,Maran J J,Jamieson E G,et al. Characterization of NLRP3 inflammasome activation in the onset of diabetic retinopathy [J]. Int J Mol Sci,2022,23(22):14471.

[27]Zheng X,Wan J,Tan G. The mechanisms of NLRP3 inflammasome/pyroptosis activation and their role in diabetic retinopathy [J]. Front Immunol,2023,14:1151185.

[28]Yun J H. Interleukin-1β induces pericyte apoptosis via the NF-κB pathway in diabetic retinopathy [J]. Biochem Biophys Res Commun,2021,546:46-53.

[29]Cho C H,Roh K H,Lim N Y,et al. Role of the JAK/STAT pathway in a streptozotocin-induced diabetic retinopathy mouse model [J]. Graefes Arch Clin Exp Ophthalmol,2022,260(11):3553-3563.

[30]Song S,Huang L,Zhou X,et al. Exploring the toxicological network in diabetic microvascular disease [J]. Int J Surg,2025,111(6):3895-3907.

[31]Sheng X,Zhang C,Zhao J,et al. Microvascular destabilization and intricated network of the cytokines in diabetic retinopathy:from the perspective of cellular and molecular components [J]. Cell Biosci,2024,14(1):85.

[32]Cao Y,Dang M,Tian Z,et al. Aqueous humor cytokine levels in patients with subretinal fibrosis in neovascular age-related macular degeneration [J]. BMC Ophthalmol,2024,24(1):335.

[33]Chen Y,Hao W,Wang M,et al. Cytokine status and significant increase of IL-6 and sIL-6R in the aqueous humor of diabetic cataract patients revealed by quantitative multiplexed assays [J]. J Int Med Res,2023,51(9):3000605231175765.

[34]Latz C,Licht A,Mirshahi A,et al. Prospective cytokine profiling in aqueous humor reveals a proinflammatory microenvironment in highly dense nuclear cataracts [J]. Invest Ophthalmol Vis Sci,2024,65(11):25.

[35]Baillif S,Nahon-Esteve S,Pace-Loscos T,et al. Aqueous humor mediator levels as biomarkers of anti-VEGF response in age-related macular degeneration [J]. Cytokine,2025,190:156921.

[36]Mat Nor M N,Guo C X,Green C R,et al. Hyper-reflective dots in optical coherence tomography imaging and inflammation markers in diabetic retinopathy [J]. J Anat,2023,243(4):697-705.

[37]Arias J D,Parra M M,Arango F J,et al. Differentiation of features of inflammatory neovascular membrane versus active posterior uveitis by SS-OCTA [J]. Ophthalmic Surg Lasers Imaging Retina,2021,52(3):129-137.

[38]Sorour O A,Levine E S,Baumal C R,et al. Persistent diabetic macular edema:definition,incidence,biomarkers,and treatment methods [J]. Surv Ophthalmol,2023,68(2):147-174.

[39]Terao R,Obata R,Okubo A,et al. Cytokine profiles in the aqueous humor following brolucizumab administration for exudative age-related macular degeneration [J]. Graefes Arch Clin Exp Ophthalmol,2023,261(9):2465-2476.

[40]Du L,Yip Y W Y,Ng H K,et al. Ruxolitinib alleviates uveitis caused by salmonella typhimurium endotoxin [J].Microorganisms,2021,9(7):1481.

[41]Daldal H,Nazıroğlu M. Rituximab attenuated lipopolysaccharide-induced oxidative cytotoxicity,apoptosis,and inflammation in the human retina cells via modulating the TRPM2 signaling pathways [J]. Ocul Immunol Inflamm,2022,30(6):1315-1328.

[42]Liao D S,Grossi F V,El Mehdi D,et al. Complement C3 inhibitor pegcetacoplan for geographic atrophy secondary to age-related macular degeneration:a randomized phase 2 trial [J]. Ophthalmology,2020,127(2):186-195.

[43]Zhang Y,Lv X,Hu Z,et al. Protection of Mcc950 against high-glucose-induced human retinal endothelial cell dysfunction [J]. Cell Death Dis,2017,8(7):e2941.

[44]Ren K,Li X. Targeting the NEK7/NLRP3 inflammasome axis:synergistic protection of intravitreal MCC950 and systemic metformin against diabetic retinopathy in rats [J].Endocrinol Diabetes Metab,2026,9(1):e70151.

Research progress on the role of inflammatory reaction in diabetic macular edema

HUANG Shengai MA Gaoen

Department of Ophthalmology, the First Affiliated Hospital of Hainan Medical University, Hainan Province, Haikou 570100, China

[Abstract] Diabetic macular edema (DME) is one of the main causes of visual impairment in diabetes retinopathy, which can occur at any stage of diabetes retinopathy. Previous studies have emphasized disruption of blood-retinal barrier mediated by vascular endothelial growth factor, and some patients have poor response to treatment with anti vascular endothelial growth factor, therefore, further exploration of other molecular pathological networks remains a key focus in this field. In recent years, “inflammation-vascular” dual drive new model can promote research progress of DME. This article analyzes activation process of key cells such as microglia and Müller cells, and explores mutual influence of important signaling pathways such as NF-κB, JAK/STAT, NLRP3 inflammasome, etc., and further discusses new diagnostic and therapeutic strategies from the perspective of inflammation, including discovery of novel biomarkers,clinical translation of targeted inflammatory drugs, and individualized treatment concepts based on inflammation classification, provides a prospect for the future direction of DME inflammation research, and offers new ideas for basic research and clinical practice of the disease.

[Key words] Diabetic macular edema; Inflammatory response; Blood-retinal barrier; Cytokines; Personalized treatment

[中图分类号] R587.2

[文献标识码] A

[文章编号] 1673-7210(2026)09(b)-0165-05

DOI:10.20047/j.issn1673-7210.25122362

[基金项目] 国家外国专家项目(G2022026027L);河南省医学科技攻关计划省部共建项目(SBGJ202102190)。

[作者简介] 黄圣嫒(1998-),女,海南医科大学第一临床医学院2023级眼科专业在读硕士研究生;研究方向:玻璃体视网膜疾病。

[通信作者] 马高恩(1979-),男,博士,副主任医师;研究方向:炎症与血管生成及玻璃体视网膜疾病。

(收稿日期:2025-12-31)

(修回日期:2026-04-11)

X